Monthly Archives: April 2019

Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
April 11, 2019

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Every morning before I go to work, I review my calendar for the day. This gets me into the

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
April 1, 2019

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with

Leave a comment

Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
April 1, 2019

Back in September 2018, the FDA approved Lilly’s Emgality, an anti-CGRP antibody therapy, for the preventative treatment of episodic and chronic migraine. Arteaus Therapeutics, a biotech company founded by Atlas Venture in 2011, played a critical role in Emgality’s early

Leave a comment